27052-16-0Relevant academic research and scientific papers
A thiazolidine compound of ketones, and its preparation for treating iron disorder related disease application of the medicament (by machine translation)
-
Paragraph 0046, (2017/02/24)
The invention discloses a thiazolidone compound, wherein a chemical structure of the thiazolidone compound is shown in a general form (I). The invention also discloses application of the thiazolidone compound in preparation of a medicine used for treating thalassemia. Experiments prove that the thiazolidone compound can be used for effectively stimulating expression of hepcidin in cells under the condition that concentration is 10mu M, can be still used for effectively inducing expression of hepcidin in liver when being exposed for 6 hours, 24 hours and 48 hours respectively at a dosage of 30mg/kg in animal level and can be also used for effectively reducing level of serum iron, so that the thiazolidone compound can take hepcidin as a target, can be used for reducing iron level in serum, is hopeful to be a potential medicine used for treating and alleviating iron disorder-related diseases and has a broad clinical application prospect and a great economic development value.
New thiazolidinyl analogs containing pyridine ring: Synthesis, biological evaluation and QSAR studies
Ranga, Reetu,Sharma, Vikas,Kumar, Vipin
, p. 1538 - 1548 (2013/07/26)
A series of pyridine derivatives of thiazolidin-4-ones (4a-4o) has been synthesized. Structures of these compounds were established on the basis of elemental analysis, IR, 1H NMR, 13C NMR, and Mass spectral data. All the synthesized compounds have been evaluated for their anti-inflammatory and analgesic effects. The results showed that compound 2-[4-methylphenylimino]-5-(1H-pyridin-2-ylmethylidene)-1,3-thiazolidin-4-one (4d), 2-(2,4-dinitro-phenylhydrazinylidine)-5-(1H-pyridin-2-yl-methylidene)-1,3- thiazolidin-4-one (4h), and 2-[3-nitro-phenylimino]-5-(1H-pyridin-2-yl- methylidene)-1,3-thiazolidin-4-one (4j) exhibited good anti-inflammatory and analgesic activity. Compound 4h was found to be the most active compound of the series with an interesting dual anti-inflammatory and analgesic activity. Docking simulation was performed to position synthesized compounds into the active site of COX-2. The relationships of energy-based docking score with analgesic and anti-inflammatory activities were also investigated by linear regression method. The QSAR models with R 2 of 0.621 and 0.740 were developed for analgesic and anti-inflammatory activities, respectively.
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells
Zhou, Hongyu,Wu, Shuhong,Zhai, Shumei,Liu, Aifeng,Sun, Ying,Li, Rongshi,Zhang, Ying,Ekins, Sean,Swaan, Peter W.,Fang, Bingliang,Zhang, Bin,Yan, Bing
, p. 1242 - 1251 (2008/12/23)
Ten cytoselective compounds have been identified from 372 thiazolidinone analogues by applying iterative library approaches. These compounds selectively killed both non-small cell lung cancer cell line H460 and its paclitaxel-resistant variant H460taxR at an IC50 between 0.21 and 2.93 μM while showing much less toxicity to normal human fibroblasts at concentrations up to 195 μM. Structure-activity relationship studies revealed that (1) the nitrogen atom on the 4-thiazolidinone ring (ring B in Figure 1) cannot be substituted, (2) several substitutions on ring A are tolerated at various positions, and (3) the substitution on ring C is restricted to the -NMe2 group at the 4-position. A pharmacophore derived from active molecules suggested that two hydrogen bond acceptors and three hydrophobic regions were common features. Activities against P-gp-overexpressing and paclitaxel-resistant cell line H460taxR and modeling using a previously validated P-gp substrate pharmacophore suggested that active compounds were not likely P-gp substrates.
